vs
景顺（IVR）与ROCKWELL MEDICAL, INC.（RMTI）财务数据对比。点击上方公司名可切换其他公司
景顺的季度营收约是ROCKWELL MEDICAL, INC.的1.2倍（$21.3M vs $18.3M），景顺净利率更高（242.2% vs -3.0%，领先245.3%），景顺同比增速更快（55.4% vs -25.6%），过去两年景顺的营收复合增速更高（74.2% vs -10.1%）
景顺是一家美国独立投资管理公司，总部位于佐治亚州亚特兰大，在全球20个国家设有分支机构。景顺旗下拥有景顺、景顺 perpetual、PowerShares等多个品牌，其普通股纳入标普500指数，在纽约证券交易所挂牌交易。
罗克韦尔医疗成立于1996年，总部位于美国密歇根州威克瑟姆，是一家上市制药企业，核心业务聚焦于终末期肾病与慢性肾病相关治疗方案的研发与商业化推广。
IVR vs RMTI — 直观对比
营收规模更大
IVR
是对方的1.2倍
$18.3M
营收增速更快
IVR
高出81.0%
-25.6%
净利率更高
IVR
高出245.3%
-3.0%
两年增速更快
IVR
近两年复合增速
-10.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.3M | $18.3M |
| 净利润 | $51.5M | $-554.0K |
| 毛利率 | — | 21.1% |
| 营业利润率 | — | -2.2% |
| 净利率 | 242.2% | -3.0% |
| 营收同比 | 55.4% | -25.6% |
| 净利润同比 | 1368.7% | 26.7% |
| 每股收益（稀释后） | $0.72 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IVRRMTI
| Q4 25 | $21.3M | $18.3M | ||
| Q3 25 | $17.6M | $15.9M | ||
| Q2 25 | $17.7M | $16.1M | ||
| Q1 25 | $18.8M | $18.9M | ||
| Q4 24 | $13.7M | $24.7M | ||
| Q3 24 | $7.5M | $28.3M | ||
| Q2 24 | $8.6M | $25.8M | ||
| Q1 24 | $7.0M | $22.7M |
净利润IVRRMTI
| Q4 25 | $51.5M | $-554.0K | ||
| Q3 25 | $53.5M | $-1.8M | ||
| Q2 25 | $-23.3M | $-1.5M | ||
| Q1 25 | $19.6M | $-1.5M | ||
| Q4 24 | $3.5M | $-756.0K | ||
| Q3 24 | $40.7M | $1.7M | ||
| Q2 24 | $-13.5M | $343.0K | ||
| Q1 24 | $29.1M | $-1.7M |
毛利率IVRRMTI
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
营业利润率IVRRMTI
| Q4 25 | — | -2.2% | ||
| Q3 25 | — | -9.9% | ||
| Q2 25 | — | -8.4% | ||
| Q1 25 | — | -7.2% | ||
| Q4 24 | — | -2.1% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | -5.8% |
净利率IVRRMTI
| Q4 25 | 242.2% | -3.0% | ||
| Q3 25 | 303.6% | -11.0% | ||
| Q2 25 | -131.6% | -9.3% | ||
| Q1 25 | 104.4% | -8.0% | ||
| Q4 24 | 25.6% | -3.1% | ||
| Q3 24 | 542.2% | 5.9% | ||
| Q2 24 | -155.9% | 1.3% | ||
| Q1 24 | 415.9% | -7.6% |
每股收益（稀释后）IVRRMTI
| Q4 25 | $0.72 | $-0.01 | ||
| Q3 25 | $0.74 | $-0.05 | ||
| Q2 25 | $-0.40 | $-0.05 | ||
| Q1 25 | $0.26 | $-0.04 | ||
| Q4 24 | $-0.09 | $-0.02 | ||
| Q3 24 | $0.63 | $0.04 | ||
| Q2 24 | $-0.38 | $0.01 | ||
| Q1 24 | $0.49 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $56.0M | $10.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $797.5M | $37.0M |
| 总资产 | $6.5B | $57.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IVRRMTI
| Q4 25 | $56.0M | $10.7M | ||
| Q3 25 | $58.5M | $13.6M | ||
| Q2 25 | $59.4M | $12.5M | ||
| Q1 25 | $42.9M | $11.4M | ||
| Q4 24 | $73.4M | $15.7M | ||
| Q3 24 | $48.3M | $12.3M | ||
| Q2 24 | $58.8M | $11.9M | ||
| Q1 24 | $59.9M | $6.6M |
股东权益IVRRMTI
| Q4 25 | $797.5M | $37.0M | ||
| Q3 25 | $769.6M | $37.0M | ||
| Q2 25 | $709.4M | $30.4M | ||
| Q1 25 | $759.2M | $31.5M | ||
| Q4 24 | $730.7M | $32.6M | ||
| Q3 24 | $857.0M | $29.1M | ||
| Q2 24 | $759.2M | $23.5M | ||
| Q1 24 | $785.6M | $20.6M |
总资产IVRRMTI
| Q4 25 | $6.5B | $57.1M | ||
| Q3 25 | $6.0B | $57.5M | ||
| Q2 25 | $5.4B | $52.6M | ||
| Q1 25 | $6.2B | $54.0M | ||
| Q4 24 | $5.7B | $59.2M | ||
| Q3 24 | $6.1B | $57.1M | ||
| Q2 24 | $5.1B | $53.0M | ||
| Q1 24 | $5.2B | $50.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $157.1M | $2.3M |
| 自由现金流经营现金流 - 资本支出 | — | $2.2M |
| 自由现金流率自由现金流/营收 | — | 12.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.05× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.2M |
8季度趋势，按日历期对齐
经营现金流IVRRMTI
| Q4 25 | $157.1M | $2.3M | ||
| Q3 25 | $37.3M | $-1.3M | ||
| Q2 25 | $40.6M | $1.8M | ||
| Q1 25 | $19.3M | $-3.5M | ||
| Q4 24 | $183.2M | $865.0K | ||
| Q3 24 | $30.8M | $4.3M | ||
| Q2 24 | $33.0M | $1.4M | ||
| Q1 24 | $57.5M | $-2.4M |
自由现金流IVRRMTI
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
自由现金流率IVRRMTI
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
资本支出强度IVRRMTI
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
现金转化率IVRRMTI
| Q4 25 | 3.05× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 52.24× | — | ||
| Q3 24 | 0.76× | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | 1.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IVR
暂无分部数据
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
